English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background People in prison represent a high-risk population for HCV infection control due the overrepresentation of people with a history of intravenous drug use, psychiatric patients and other vulnerable populations who have often reduced access to healthcare. With the advent of new direct antiviral agents (DAAs) HCV micro-elimination in prison setting became a feasible strategy. Methods We conducted in 2017 and 2018 a cross-sectional evaluation of HCV treatment cascade in one detention prison, Opera (OP), and one pre-trial detention center, San Vittore (SV) in Milan. A dedicated protocol for HCV eligibility and care was applied. We collected data on demographics, HCV testing and treatment on all inmates on October 31st 2017 and 2018. Data collection ended on December 31st of each year. Results On October 31st 2017, 2366 inmates were living in the two facilities, 2369 in 2018, of these, 1036 (43,7%) were already present in 2017 (71,3% in OP; 28,7% in SV). In both years the majority were men (95.4%; 96,4%) with a median age of 41 years and Italians (57%; 61,9%). Prevalence of reported drug use remained high (46,5%; 44,2%). HCV screening coverage was 89% in both years, while HCV-RNA test coverage increased (90,6%; 99%). HCV Ab+ was stable (212, 10.1%; 194, 9,2%). At the end of 2017 and 2018, 106 (50%) and 117 (60,3%) started treatment eligibility process of which 90 (42,4%) and 106 (54,6%) completed DAAs in prison. Considering last available viremia, 41 inmates (19,3%) were viremic in 2017 (OP 16.1%; SV 24,4%), while only 13 inmates (6,7%) in 2018 (OP &amp;lt; 1%, SV 15,4%). On December 31st 2018, among HCV Ab+ detainees 122 (62,9%) were never linked to care before incarceration. Conclusions Our study shows the success of the HCV testing and treatment strategy to achieve HCV micro-elimination in a prison setting with a significant drop in the pool of viremic individuals. We highlight how prison health care may represent a unique point of access for vulnerable population. Key messages HCV micro-elimination is a feasible and effective strategy in prison settings. High-quality healthcare in prison contributes to reduce health gaps and improve access for socially deprived population.

HCV test&treat in Milan prisons-an effective strategy for microelimination and health gaps reduction